This review highlights the increasing incidence of breast cancer, making it a major health concern for women globally. While most cases can be treated with surgery and endocrine drugs, triple-negative breast cancer (TNBC) poses a significant challenge due to limited effective treatments. Nectin-4, previously limited to specific tissues, has emerged as a potential therapeutic target. Overexpressed in breast cancer, Nectin-4 plays a crucial role in tumor formation, proliferation, and metastasis. Current treatments, including chemotherapy and targeted therapy, have limitations, necessitating new strategies. Nectin-4, identified as a breast cancer stem cell marker, holds promise for TNBC prognosis. This review provides valuable insights for researchers and clinicians, outlining potential directions for further studies and therapies.
